Ferreira JP, et al. - Researchers evaluated the potential advantage of mineralocorticoid receptor antagonists (MRAs) in myocardial infraction (MI) with ejection fraction (EF) of 40% in the Eplerenone in Patients with Left Ventricular Dysfunction after Myocardial Infarction trial. The study sample consisted of 6,632 patients, among whom 11% had an EF of 40% and heart failure or diabetes. The investigators used Cox models with interaction term for EF. A composite of cardiovascular death or hospitalization for cardiovascular causes was assessed as the primary outcome. They found that the attenuation in hospitalizations and mortality brought about by eplerenone in patients with MI and EF equal to 40% was similar to reductions it provided in patients with an EF < 40%. The possible beneficial effect of MRA therapy in MI patients with EF in the “mid-range zone” was suggested in this study.